Latest News...

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis
read more »

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis
read more »

Advancing Foundational Medicine
to Treat Orphan Inflammatory Disease

Neutrophil modulation platform reduces inflammation

Focused on orphan diseases

Enrolling Acebilustat Phase 2B CF Lung Preservation Trial

  • Acebilustat is a first–in-class, small molecule medicine
    • Issued COM IP through 2027 + Extensions
  • Neutrophils play critical role in pathogenesis of many hyper-immune diseases
    • Respiratory, Dermatology, Cardiovascular, Gastrointestinal
  • High unmet need and favorable development/commercial pathway
  • Acebilustat granted orphan designation in CF in US and EU
  • CF Foundation partnership
  • Targets all patients, irrespective of gene mutation
  • Clear potential to reduce lung clogging and lung damage

Pipeline of Multiple Orphan Disease Opportunities

Program Pre Clinical Phase I Phase II Phase III
Acebilustat CF        
Acebilustat HS        
(Topical Pro-drug)
(Second Gen Oral)

Cystic Fibrosis: Lung Inflammation Drives Morbidity & Mortality

Persistent, high-intensity lung inflammation leads to:

  • Airway obstruction
  • Pulmonary exacerbation
  • Permanently impaired lung function

CF lung inflammation is neutrophil driven and starts as early as 3 months of age. Respiratory failure & pre-mature death at 35-40 years of age.

More »

Orphan Inflammatory Disease Targets

Orphan Disease Chart

Learn More »

About Celtaxsys

Latest News